Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.
about
Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-upCost of managing an episode of relapse in multiple sclerosis in the United StatesPersonalized medicine in multiple sclerosis: hope or reality?Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.Emergency medical care of multiple sclerosis patients: primary data from the mount sinai resource utilization in multiple sclerosis project.Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis.Sex hormones: a role in the control of multiple sclerosis?Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?Validity of patient-derived disability and clinical data in multiple sclerosis.Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.Physicians, subsequence and consequence.Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in Møre and Romsdal, Norway.Genetic epidemiology of multiple sclerosisRole of the innate immune system in the pathogenesis of multiple sclerosis.Multiple sclerosis-A disease on a dramatically rising trend in Iran: Review of possible reasonsEvidence for a two-stage disability progression in multiple sclerosisHigh-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.Aggressive multiple sclerosis: proposed definition and treatment algorithm.Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up.Sex-specific quantitative trait loci govern susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinationBenign multiple sclerosis: does it exist?Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis.Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futureRelapses and disability accumulation in progressive multiple sclerosisAge and disability accumulation in multiple sclerosis.A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS)Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis.Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors.Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curvesDisability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.Multiple sclerosis: diagnosis and the management of acute relapsesMulticentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.Clinical characteristics of multiple sclerosis in Västerbotten County in northern Sweden.Predictors of disability worsening in clinically isolated syndrome.Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.A 30-year-old woman with vision loss and painful eye movements.Lesion Activity on Brain MRI in a Chinese Population with Unilateral Optic NeuritisPoor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
P2860
Q24650224-9BF72966-3D80-4DB6-8B7F-0FD15C37CD50Q24801495-CEE7C71D-0901-4069-9077-961C64213D01Q27025933-98EA740E-E615-4C12-A35E-EBE6370921E4Q30712257-AC67E8E1-5593-4833-8833-443C75E5DDF7Q30837613-6CC51ADF-2A93-4799-9758-933CE6A99924Q30996206-0F8DA19E-A760-4F29-AF38-EE94CEEFA87CQ31037759-0430DC04-0BE5-4103-9F45-293E08D4DF6CQ33289264-9222DEA7-D092-40A8-AF53-2EAFFAB2B372Q33530812-D40325F0-ECAF-4A09-9BFA-256435A5357AQ33643239-C3801CFD-56EB-4DBB-9A26-85B1BD9F17EAQ33712704-6ED62C4B-2A2F-41D8-8705-86EC24E15445Q33733925-7327BBBD-8C82-4CCA-BDD1-3CDC9515FA0DQ33735806-C2F3B5DE-90BD-4105-801E-6FDB04495BCBQ33787624-40D95795-0629-4BF9-8D06-FF17FCF30183Q33896817-E2B0C619-EB89-400F-916D-CEAD73E2F250Q33944184-47B6050F-49FF-497A-A32A-27C4BBC4B90AQ34237823-28ABEFA8-93E3-4B71-8B24-8DF447E40644Q34478828-6EE31BD5-8EDB-45C3-AFC3-8B25C5B2DFC8Q34479121-4BFC5E46-44A9-46F6-BFA3-738F0FB3F736Q34561939-E509D43F-50ED-41CF-BB42-F34D7033B090Q34617232-4CB58C30-FDBF-4BCD-9803-D8C31A897283Q34640135-114AA712-5F68-432A-9BB0-88EF67958FF2Q34758029-69383DE0-6B14-42EA-A420-498B607B4DCAQ35078327-33D88767-8AD9-4C9C-A80F-D01F22AA01EDQ35106567-9F36DE7C-9538-45F9-B660-23F3EC9D4CF8Q35230950-A550D4E6-67D2-4813-904A-1D892C8B2BCFQ35305266-B3817880-5A92-434D-B564-163097CACE37Q35450216-C84F6DEA-201A-4762-A0A4-C5C186102B1FQ35452477-BD9AE731-C522-42D0-AC19-AB3B612F18C2Q35453326-9AAC67BC-F94C-4BFC-94CC-0A9B8C2F4717Q35456042-BB695FAF-226E-443A-B179-812A643A8191Q35485799-773A996A-3DFF-4CB7-9B18-5A9B4F863550Q35521828-66C47A0E-5E7D-4DFD-A1AA-5423CE340740Q35572581-D52EF11E-36D6-4814-BDA5-2137E6674D63Q35572600-77373FF4-2796-47AE-88D9-0E611EA9AD28Q35619185-C3F4CDFB-BAED-4A28-9797-C53C12560E79Q35629319-3DAB35D9-E528-490F-ABE0-0247871E407DQ35744005-CE4DB925-9DB4-41F1-AC15-0EA5E247D7F9Q35815017-CD99A281-AF57-4A7C-A8BF-9FB19A414B8CQ36005655-C86D5367-E9E0-466A-8EDE-51110B6B7A13
P2860
Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Prognostic factors in a multip ...... wenty-five years of follow-up.
@en
Prognostic factors in a multip ...... wenty-five years of follow-up.
@nl
type
label
Prognostic factors in a multip ...... wenty-five years of follow-up.
@en
Prognostic factors in a multip ...... wenty-five years of follow-up.
@nl
prefLabel
Prognostic factors in a multip ...... wenty-five years of follow-up.
@en
Prognostic factors in a multip ...... wenty-five years of follow-up.
@nl
P356
P1433
P1476
Prognostic factors in a multip ...... wenty-five years of follow-up.
@en
P2093
Andersen O
Runmarker B
P304
P356
10.1093/BRAIN/116.1.117
P407
P478
116 ( Pt 1)
P577
1993-02-01T00:00:00Z